Effects of Ginkgo biloba on Blood Coagulation Parameters

A Systematic Review of Randomised Clinical Trials


A systematic literature review was conducted to investigate the effects of Ginkgo biloba preparations on blood coagulation parameters. Systematic literature searches were carried out using MEDLINE (via PubMed), EMBASE, AMED, CINAHL®, the Cochrane Library and PsycINFO to identify randomised, double-blind, clinical trials of G. biloba mono-preparations assessing at least one blood coagulation parameter as either a primary or a supplementary outcome measure. Five manufacturers of G. biloba preprations were asked to contribute any unpublished material. Data were validated and extracted independently by two reviewers according to pre-specified criteria.

Eight trials were included, of which two included healthy subjects, four included patients with various conditions and two included participants taking concomitant anticoagulant medication, one with acetylsalicylic acid (ASA; aspirin) and one with warfarin. Overall results do not provide evidence that G. biloba does affect blood coagulation parameters in a clinically relevant manner. Out of many parameters assessed, four coagulation parameters from three studies were significantly different in the treatment group compared with the control. One study comparing the treatments of ASA and G. biloba with ASA alone confirmed that the two treatments were equivalent with regards to all but three coagulation parameters.

Available evidence does not demonstrate that extract of G. biloba causes significant changes in blood coagulation parameters. A limited number of studies on concomitant use of G. biloba with ASA or warfarin also do not suggest that G. biloba has an additive effect to the clinical effects of these two drugs. Currently available evidence is limited and, therefore, further studies are needed to assess effects of G. biloba on a variety of blood coagulation parameters.

This is a preview of subscription content, access via your institution.

Fig. 1
Table I
Table II
Table III
Table IV
Table V


  1. 1.

    The use of trade names is for product identification purposes only and does not imply endorsement.

  2. 2.

    Only raw data were presented in the report. Statistical analysis was carried out by an author of this article (JS) using SPSS® version 11.5 for Windows® (SPSS Inc., Chicago, IL, USA)


  1. 1.

    Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996; 46(6): 1775–6

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Gilbert GJ. Ginkgo biloba [letter]. Neurology 1997; 48(4): 1137

    PubMed  Article  CAS  Google Scholar 

  3. 3.

    Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba [letter]. Lancet 1998; 352(9121): 36

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Benjamin J, Muir T, Briggs K, et al. A case of cerebral haemorrhage: can Ginkgo biloba be implicated?. Postgrad Med J 2001; 77(904): 112–3

    PubMed  Article  CAS  Google Scholar 

  5. 5.

    Fessenden J, Wittenborn W, Clarke L. Gingko biloba: a case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy. Am Surg 2001; 67(1): 33–5

    PubMed  CAS  Google Scholar 

  6. 6.

    Fong KCS, Kinnear PE. Retrobulbar haemorrhage associated with chronic Gingko biloba ingestion. Postgrad Med J 2003; 79(935): 531–2

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract [letter]. N Engl J Med 1997; 336(15): 1108

    PubMed  Article  CAS  Google Scholar 

  8. 8.

    Matthews MK, Lewis SL, Rowin J. Association of Ginkgo biloba with intracerebral hemorrhage [multiple letters]. Neurology 1998; 50(6): 1933–4

    PubMed  Article  Google Scholar 

  9. 9.

    Meisel C, Johne A, Roots I. Fatal intracerebral mass bleeding associated with Ginkgo biloba and ibuprofen [letter]. Atherosclerosis 2003; 167(2): 367

    PubMed  Article  CAS  Google Scholar 

  10. 10.

    Ernst E, Canter PH, Thompson-Coon J. Does Ginkgo biloba increase the risk of bleeding? A systematic review of case reports. Perfusion 2005; 18(2): 52–6

    Google Scholar 

  11. 11.

    Guinot P, Braquet P, Duchier J, et al. Inhibition of PAF-acether induced weal and flare reaction in man by a specific PAF antagonist. Prostaglandins 1986; 32(1): 160–3

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Braquet P, Hosford D. Ethnopharmacology and the development of natural PAF antagonists as therapeutic agents. J Ethnopharmacol 1991; 32(1–3): 135–9

    PubMed  Article  CAS  Google Scholar 

  13. 13.

    Chung KF, Dent G, McCusker M, et al. Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man. Lancet 1987; I(8527): 248–51

    Article  Google Scholar 

  14. 14.

    Braquet P. Cedemin, a Ginkgo biloba extract, should not be considered as a PAF antagonist [letter]. Am J Gastroenterol 1993; 88(12): 2138

    PubMed  CAS  Google Scholar 

  15. 15.

    Morris CA, Avorn J. Internet marketing of herbal products. JAMA 2003; 290(11): 1505–9

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Morgenstern C, Biermann E. The efficacy of Ginkgo special extract EGb 761 in patients with tinnitus. Int J Clin Pharmacol Ther 2002; 40(5): 188–97

    PubMed  CAS  Google Scholar 

  17. 17.

    Schneider LS, DeKosky ST, Farlow MR, et al. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer’s type. Curr Alzheimer Res 2005; 2(5): 541–51

    PubMed  Article  CAS  Google Scholar 

  18. 18.

    Kanowski S, Herrmann WM, Stephan K, et al. Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996; 29(2): 47–56

    PubMed  Article  CAS  Google Scholar 

  19. 19.

    Morgenstern C, Biermann E. Ginkgo-Spezialextrakt EGb 761 in der Behandlung des Tinnitus aurium. Ergebnisse einer randomisierten, doppelblinden, plazebokontrollierten Studie. Fortschr Med Orig 1997; 115(4): 7–11

    Google Scholar 

  20. 20.

    Taillandier J, Ammar A, Rabourdin JP, et al. Traitement des troubles du viellissement cérébral par l’extrait de Ginkgo biloba. Etude longitudinale, multicentrique à double insu face au placebo. Presse Méd 1986; 15(31): 1583–7

    PubMed  CAS  Google Scholar 

  21. 21.

    Thomson GJL, Vohra RK, Carr MH, et al. A clinical-trial of Ginkgo-biloba extract in patients with intermittent claudication. Int Angiol 1990; 9(2): 75–8

    PubMed  CAS  Google Scholar 

  22. 22.

    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996; 17(1): 1–12

    PubMed  Article  CAS  Google Scholar 

  23. 23.

    Bal Dit Sollier C, Caplain H, Drouet L. No alteration in platelet function or coagulation induced by EGb761 in a controlled study. Clin Lab Haematol 2003; 25(4): 251–3

    PubMed  Article  CAS  Google Scholar 

  24. 24.

    Köhler S, Funk P, Kieser M. Influence of a 7-day treatment with Ginkgo biloba special extract EGb 761 on bleeding time and coagulation: a randomized, placebo-controlled, double-blind study in healthy volunteers. Blood Coagul Fibrinolysis 2004; 15(4): 303–9

    PubMed  Article  Google Scholar 

  25. 25.

    Hofferberth B. Simultanerfassung elektrophysiologischer, psychometricher und Theologischer Parameter bei Patienten mit hirnorganischem Psychosyndrom und erhoehtem Gefaessrisiko — Eine Placebo-kontrollierte Doppelblind-studie mit Ginkgo biloba-Extrakt EGb 76. In: Stodtmeister R, Pillunat L, editors. Mikrozirkulation in Gehirn und Sinnesorganen. Stuttgart: Enke, 1991

    Google Scholar 

  26. 26.

    Mancini M, Agozzino B, Bompani R. Effetti clinico-terapeutici dell’estrato di Ginkgo biloba (Egb) in confronte a placebo, nel trattamento di pazienti affetti da demeza psicorganica senile su base arteriosclerotica. Gazz Med Ital Arch Sci Med 1993; 152(3): 69–80

    Google Scholar 

  27. 27.

    Muir AH, Robb R, McLaren M, et al. The use of Ginkgo biloba in Raynaud’s disease: a double-blind placebo-controlled trial. Vasc Med 2002; 7(4): 265–7

    PubMed  Article  Google Scholar 

  28. 28.

    Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients: a randomised, double blind, placebo-crossover trial. Thromb Haemost 2002; 87(6): 1075–6

    PubMed  CAS  Google Scholar 

  29. 29.

    Engelsen J, Nielsen JD, Hansen KF. Effekten af Coenzym Q10 og Ginkgo biloba pa warfarindosis hos patienter i laengerevarende warfarinbehandling. Et randomisert, dobbelblindt, placebokontrolleret overkrydsningsforsog. Ugeskr Laeger 2003; 165(18): 1868–71

    PubMed  Google Scholar 

Download references


The fellowship of JS was funded by Dr. Willmar Schwabe Pharmaceuticals, the manufacturer of Ginkgo biloba preparations. Dr. Willmar Schwabe Pharmaceuticals are currently funding the post for one research fellow (not involved in this manuscript) in the Complementary Medicine group in Exeter. No further conflicts of interest known.

Author information



Corresponding author

Correspondence to Dr Jelena Savović.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Savović, J., Wider, B. & Ernst, E. Effects of Ginkgo biloba on Blood Coagulation Parameters. Evid-Based-Integrative-Med 2, 167–176 (2005). https://doi.org/10.2165/01197065-200502030-00007

Download citation


  • Warfarin
  • Bleeding Time
  • Intergroup Difference
  • Coagulation Parameter
  • Ginkgo Biloba Extract